ENCell Secures US Clinical Manufacturing Contract for Ingenium’s AML-Targeting NK Cell Therapy, ‘gengleucel’

KBR South Korea

Overview

ENCell, a CDMO specializing in cell and gene therapies, has secured a manufacturing contract for Ingenium Therapeutics’ allogeneic NK cell therapy candidate, ‘gengleucel,’ for U.S. clinical trials. This therapy targets minimal residual disease (MRD) in AML and incorporates Ingenium’s proprietary Memory NK cell technology. With FDA Orphan Drug designation and positive feedback on skipping Phase 1 directly to Phase 2, the development is expected to accelerate significantly.

In Depth

Key Findings

ENCell, a South Korean CDMO (Contract Development and Manufacturing Organization) specializing in cell and gene therapies, has secured a manufacturing contract for clinical trial materials of ‘gengleucel,’ an allogeneic NK cell therapy candidate being developed by U.S.-based Ingenium Therapeutics. This agreement is critically important as gengleucel is an innovative therapy targeting minimal residual disease (MRD) in acute myeloid leukemia (AML) and incorporates Ingenium’s proprietary Memory NK cell technology. Notably, gengleucel has received Orphan Drug designation from the U.S. FDA, and Ingenium has received positive feedback from the FDA regarding its plan to bypass Phase 1 trials and proceed directly to Phase 2, significantly accelerating development.

Technical / Clinical Details

Gengleucel is an allogeneic (donor-derived) NK cell therapy based on Ingenium Therapeutics’ unique Memory NK cell technology. Memory NK cells are expected to exhibit superior proliferative capacity, anti-tumor activity, and long-term persistence compared to conventional NK cells. Minimal Residual Disease (MRD) in AML is a major factor causing relapse even after complete remission, and therapies that effectively target MRD have the potential to significantly improve patient prognosis. ENCell possesses extensive experience and expertise in manufacturing such advanced cell therapies, providing manufacturing capabilities that comply with stringent GMP standards. The FDA’s allowance to skip Phase 1 is based on strong preclinical data and evidence of the mechanism of action, indicating an expedited drug development pathway.

Background & Context

NK cell therapy is gaining attention as a next-generation cancer immunotherapy, similar to CAR-T cell therapy, but with the advantage of a lower risk of severe side effects such as cytokine release syndrome (CRS) and neurotoxicity observed with CAR-T therapies. Allogeneic NK cell therapy, in particular, unlike autologous cell therapy, can be provided as an off-the-shelf product, which is expected to reduce manufacturing costs, enable faster patient supply, and improve treatment access. AML is a disease with a poor prognosis, and there is a strong demand for new treatment options. CDMOs specializing in the manufacturing of such complex cell therapies alleviate the burden on developing companies, contributing to the rapid commercialization of innovative treatments.

Strategic Significance & Outlook

The signing of this manufacturing contract is a crucial milestone for Ingenium Therapeutics’ gengleucel to rapidly advance into later stages of clinical development. Favorable results in Phase 2 trials would not only offer new hope for AML patients but also represent a significant step towards the commercialization of NK cell therapy. For ENCell, this establishes its presence as a cell therapy CDMO in the U.S. market, creating opportunities for further growth. Investors will be closely watching companies with promising pipelines in the cell and gene therapy sector, supported by advanced manufacturing platforms.